Stephen M. Ansell, MD, PhD: Nivolumab Moves to Hematology

Dr. Ansell, a speaker in the Special Education Session on Newly Approved Drugs, discusses the growing role of nivolumab in hematologic malignancies.

Array ( [_vc_post_settings] => Array ( [0] => a:1:{s:10:"vc_grid_id";a:0:{}} ) [_edit_lock] => Array ( [0] => 1489693434:22 ) [_edit_last] => Array ( [0] => 22 ) [slide_template] => Array ( [0] => ) [_wpb_vc_js_status] => Array ( [0] => true ) [_yoast_wpseo_content_score] => Array ( [0] => 30 ) [article_author] => Array ( [0] => null ) [_article_author] => Array ( [0] => field_5877b1cb5cc63 ) [_yoast_wpseo_primary_category] => Array ( [0] => 35 ) [_yoast_wpseo_primary_article_month] => Array ( [0] => ) [_yoast_wpseo_primary_article_year] => Array ( [0] => ) [_yoast_wpseo_primary_volume] => Array ( [0] => ) [_yoast_wpseo_primary_issue] => Array ( [0] => ) [_oembed_5766aedfe39b029877bfd924507866ac] => Array ( [0] => ) [_oembed_time_5766aedfe39b029877bfd924507866ac] => Array ( [0] => 1488908945 ) [td_post_video] => Array ( [0] => a:2:{s:8:"td_video";s:68:"https://youtu.be/-v8kSNCfzUw?list=PL4C8vBKsIWMpFdUH2fk2Juo2spvD1M1U8";s:13:"td_last_video";s:68:"https://youtu.be/-v8kSNCfzUw?list=PL4C8vBKsIWMpFdUH2fk2Juo2spvD1M1U8";} ) [_thumbnail_id] => Array ( [0] => 10184 ) [_oembed_42c378688587073689fab393fa154563] => Array ( [0] => ) [_oembed_time_42c378688587073689fab393fa154563] => Array ( [0] => 1488908993 ) [post_views_count] => Array ( [0] => 0 ) [td_post_theme_settings] => Array ( [0] => a:1:{s:16:"td_post_template";s:18:"single_template_10";} ) [_encloseme] => Array ( [0] => 1 ) )
SHARE